NextCure, Inc. (NXTC)
NMS · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.3M | -8.9M | -9.8M | -10.1M |
| Net Income | -26.8M | -8.6M | -9.4M | -9.8M |
| Diluted EPS | $-11.29 | $-3.22 | $nan | $-1.87 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -75.9M | -67.6M | -57.2M | -57.6M |
| Net Income | -74.7M | -62.7M | -55.7M | -55.8M |
| Diluted EPS | $-32.28 | $-27.00 | $-23.88 | $-19.65 |